US Biosecure Act, China Plus One, and Trump’s Tariff War: CDMOs Are Hot Topic, As This Small-Cap Pharma Gains 2.66% on CDMO Expansion
US Biosecure Act, China Plus One, and Trump’s Tariff War: CDMOs Are Hot Topic, As This Small-Cap Pharma Gains 2.66% on CDMO Expansion

US Biosecure Act, China Plus One, and Trump’s Tariff War: CDMOs Are Hot Topic, As This Small-Cap Pharma Gains 2.66% on CDMO Expansion

Regulatory changes, such as the US Biosecure Act, may accelerate growth for CDMO businesses. However, uncertainties remain, especially if Donald Trump returns to power. Trump has criticized India on trade issues, including pharmaceutical tariffs, which could impact domestic pharma strategies.

Abhishek Wani Article rating: 5.0

Regulatory changes, such as the US Biosecure Act, may accelerate growth for CDMO businesses. However, uncertainties remain, especially if Donald Trump returns to power. Trump has criticized India on trade issues, including pharmaceutical tariffs, which could impact domestic pharma strategies.

DSIJ MINDSHARE

Mkt Commentary24-Feb, 2025

Mindshare21-Feb, 2025

Penny Stocks24-Feb, 2025

Mindshare24-Feb, 2025

Penny Stocks24-Feb, 2025

Knowledge

Knowledge24-Feb, 2025

Knowledge24-Feb, 2025

General24-Feb, 2025

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR